Abstract
Critical transition theory suggests that complex systems should experience increased temporal variability just before abrupt change, such as increases in clinical biomarker variability before mortality. We tested this in the context of hemodialysis using 11 clinical biomarkers measured every two weeks in 763 patients over 2496 patient-years. We show that variability – measured by coefficients of variation – is more strongly predictive of mortality than biomarker levels. Further, variability is highly synchronized across all biomarkers, even those from unrelated systems: the first axis of a principal component analysis explains 49% of the variance. This axis then generates powerful predictions of all-cause mortality (HR95=9.7, p<0.0001, where HR95 is a scale-invariant metric of hazard ratio across the predictor range; AUC up to 0.82) and starts to increase markedly ∼3 months prior to death. Such an indicator could provide an early warning sign of physiological collapse and serve to either trigger intervention or initiate discussions around palliative care.
Competing Interest Statement
AAC is Founder and CEO at Oken Health. FD is CTO at Oken Health.
Funding Statement
This work was supported by the Canadian Institutes of Health Research (CIHR, grant #153011 awarded to AAC) and by the Fonds de recherche du Quebec - Societe et culture (FRQSC, grant 2020-AUDC-270433 awarded to AAC, DG, FGB, and TF). AAC is supported by a Fonds de recherche du Quebec - Sante (FRQ-S) Senior Salary Award and is a member of the FRQ-S funded Centre de recherche du CHUS and Centre de recherche sur le vieillissement.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project received ethical approval by the Comite d'ethique de la recherche du CIUSSS de l'Estrie - CHUS (#2015-788, 14-059). Written informed consent for participation was not required for this study in accordance with the National Legislation and the Institutional Requirements, due to the retrospective nature of the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data presented in this article cannot be made publicly available, due to confidentiality concerns, transfer, and sharing of individual-level data. Data used in this study require prior approval from the CIRESSS and the Director of Professional Services of the CHUS, as well as by the Comite d'Ethique de la Recherche du CIUSSS de l'Estrie - CHUS. Requests to access the datasets should be directed to https://www.crchus.ca/en/services-outils/autresservices-et-outils/infocentre/.
